A Phase 2 interventional study of robatumumab in Osteosarcoma, Sarcoma, Ewing's and Peripheral Neuroectodermal Tumor, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2018-08-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Participants with relapsed osteosarcoma that can be treated with surgery will be randomized to robatumumab administered intravenously (IV) at one of two dose levels. These participants will first receive robatumumab, have surgery performed, and continue to receive treatment every two weeks until a year of dosing, or until disease progression.
Participants with unresectable osteosarcoma or Ewing Sarcoma will receive robatumumab IV once every two weeks until disease progression. Participants who achieve a complete response (CR) or partial response (PR) after tumor evaluations may undergo surgical resection. After surgery, participants are eligible to receive 10 mg/kg robatumumab until disease recurrence/progression or one year of total dosing, whichever occurs first.
Participants with resectable osteosarcoma will be randomized to one of two dose levels of robatumumab to be given intravenously. These participants will first receive robatumumab according to randomized treatment, and have surgery performed 10 to 14 days after initial dosing. Participants will be allowed to recover from surgery four to six weeks prior to additional robatumumab administration at their randomized dose level. robatumumab will then be administered on the same calendar day once every two weeks. Participants will continue to receive robatumumab until disease recurrence, or until completing a year of dosing at the same dose level assigned, whichever occurs first.
Participants with unresectable osteosarcoma or Ewing Sarcoma will be assigned treatment to robatumumab IV administered once every two weeks and will continue to receive robatumumab until disease progression. Participants who achieve a CR or PR after tumor evaluations may undergo surgical resection. After surgery, participants are eligible to receive 10 mg/kg robatumumab until disease recurrence/progression or one year of total dosing, whichever occurs first.
250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.
This study's enrollment of 219 is above the median of 36 across 204 interventional studies indexed under Sarcoma, Ewing.
Browse Sarcoma, Ewing studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Sarcoma, Ewing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteosarcoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A participant with either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
Biological: robatumumab
Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
Biological: robatumumab
Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
Biological: robatumumab
Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
Biological: robatumumab
Robatumumab IV every two weeks until disease progression.
Also known as: SCH 717454, SCH 717454 (19D12), MK-7454
Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only)
This is a measure of the number of participants with a complete response (CR) or partial response (PR) to therapy, confirmed by central review. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.
Time frame: Up to 1 year following the start of study therapy
Number of Participants With >= 25% Change in Tumor Proliferation After Exposure to Robatumumab (Group 1 Only)
Tumor proliferation was measured using Ki-67 levels. Ki-67 is nuclear protein associated with cellular proliferation.
Time frame: Approximately 14 days
Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only)
Responses to treatment (complete response, partial response, or stable disease) confirmed by central review for Participants in Group 2. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.
Time frame: Up to 1 year following the start of study therapy
Overall Survival
This is a measure of the number of participants known to be alive at the time of data analysis for this study.
Time frame: From start of treatment until death or data analysis cut off (Up to 3.4 years)
Time Until Tumor Relapse (Group 1 Only)
This is a measure of the time from the start of the study to documented relapse of disease.
Time frame: From start of treatment until relapse or data analysis cut off (Up to 3.4 years)
Area Under the Concentration-time Curve (AUC) of Serum Levels of Robatumumab (Group 1 Only)
Time frame: End of infusion on Day 1, and then prior to surgery, before and after the 2nd, 3rd, and 8th doses (up to 20 weeks)
Incidence of Anti-robatumumab Antibodies
For biological agents, it is possible for the host (participant) to develop antibodies to the agent. This outcome measure was planned to find out the number of participants who developed the antibodies after treatment with robatumumab.
Time frame: Up to 2 years
Number of Participants Experiencing Treatment-Emergent Adverse Events
An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Treatment-emergent adverse events are those that occur after participants have received study treatment, or existing adverse events that occurred during screening that increase in severity after study treatment. Adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.
Time frame: Up to 2 years
Time to Disease Progression (Groups 2 and 3 Only)
This is a measure of the time from the start of the study to the time of documented disease progression.
Time frame: From the start of treatment until disease progression or data analysis cut off (Up to 3.4 years)
Overall Survival (Groups 2 and 3 Only)
This is a measure of the time of survival from first dose to documentation of death
Time frame: From start of treatment until death or data analysis cut off (Up to 3.4 years)
Duration of Response (Groups 2 and 3 Only)
This is a measure of the amount of time in which the tumor responded to therapy.
Time frame: From time of documented response until disease progression or data analysis cut off (Up to 3.4 years)
| Milestone | Group 1: 0.3 mg/kg | Group 1: 10 mg/kg | Group 2: 10 mg/kg | Group 3: 10 mg/kg |
|---|---|---|---|---|
| Started | 35 | 33 | 35 | 116 |
| Received treatment | 34 | 33 | 34 | 115 |
| Completed | 4 | 5 | 0 | 1 |
| Not completed | 31 | 28 | 35 | 115 |
| Withdrew: Treatment ongoing at data cut-off | 0 | 0 | 0 | 5 |
| Withdrew: Lack of efficacy | 23 | 26 | 30 | 97 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 | 0 | 2 |
| Withdrew: Protocol violation | 2 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 3 | 8 |
| Withdrew: Not treated | 1 | 0 | 1 | 1 |
This is a measure of the number of participants with a complete response (CR) or partial response (PR) to therapy, confirmed by central review. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.
| Participants | Group 3: 10 mg/kg |
|---|---|
| Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only) | 6 |
Tumor proliferation was measured using Ki-67 levels. Ki-67 is nuclear protein associated with cellular proliferation.
No measurements were reported for this outcome.
Responses to treatment (complete response, partial response, or stable disease) confirmed by central review for Participants in Group 2. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria.
| Participants | Group 2: 10 mg/kg |
|---|---|
| Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only) | 6 |
This is a measure of the number of participants known to be alive at the time of data analysis for this study.
| Participants | Group 1: 0.3 mg/kg | Group 1: 10 mg/kg | Group 2: 10 mg/kg | Group 3: 10 mg/kg |
|---|---|---|---|---|
| Overall Survival | 17 | 16 | 7 | 28 |
This is a measure of the time from the start of the study to documented relapse of disease.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
For biological agents, it is possible for the host (participant) to develop antibodies to the agent. This outcome measure was planned to find out the number of participants who developed the antibodies after treatment with robatumumab.
No measurements were reported for this outcome.
An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Treatment-emergent adverse events are those that occur after participants have received study treatment, or existing adverse events that occurred during screening that increase in severity after study treatment. Adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.
| Participants | Group 1: 0.3 mg/kg | Group 1: 10 mg/kg | Group 2: 10 mg/kg | Group 3: 10 mg/kg |
|---|---|---|---|---|
| Number of Participants Experiencing Treatment-Emergent Adverse Events | 31 | 30 | 31 | 112 |
This is a measure of the time from the start of the study to the time of documented disease progression.
No measurements were reported for this outcome.
This is a measure of the time of survival from first dose to documentation of death
| Months | Group 2: 10 mg/kg | Group 3: 10 mg/kg |
|---|---|---|
| Overall Survival (Groups 2 and 3 Only) | 8.18 (2.96 to 10.58) | 6.93 (4.93 to 11.10) |
This is a measure of the amount of time in which the tumor responded to therapy.
No measurements were reported for this outcome.
Collected over Adverse events are reported from enrollment up to 5 weeks after the end of treatment (up to 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: 0.3mg/kg | — | 17/34 (50%) | 28/34 (82.4%) |
| Group 1: 10mg/kg | — | 8/33 (24.2%) | 30/33 (90.9%) |
| Group 2: 10mg/kg | — | 12/34 (35.3%) | 29/34 (85.3%) |
| Group 3: 10mg/kg | — | 57/115 (49.6%) | 104/115 (90.4%) |
| Event | Group 1: 0.3mg/kg | Group 1: 10mg/kg | Group 2: 10mg/kg | Group 3: 10mg/kg |
|---|---|---|---|---|
| PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders | 4/34 | 1/33 | 0/34 | 1/115 |
| PAINGeneral disorders | 0/34 | 1/33 | 0/34 | 11/115 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 3/34 | 1/33 | 0/34 | 5/115 |
| PYREXIAGeneral disorders | 1/34 | 1/33 | 0/34 | 7/115 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 2/34 | 0/33 | 0/34 | 0/115 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/34 | 0/33 | 2/34 | 3/115 |
| RESPIRATORY DISTRESSRespiratory, thoracic and mediastinal disorders | 0/34 | 0/33 | 0/34 | 6/115 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/34 | 0/33 | 1/34 | 4/115 |
| CHEST PAINGeneral disorders | 0/34 | 0/33 | 1/34 | 4/115 |
| CONSTIPATIONGastrointestinal disorders | 0/34 | 1/33 | 0/34 | 2/115 |
| Event | Group 1: 0.3mg/kg | Group 1: 10mg/kg | Group 2: 10mg/kg | Group 3: 10mg/kg |
|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 13/34 | 12/33 | 5/34 | 35/115 |
| PROCEDURAL PAINInjury, poisoning and procedural complications | 13/34 | 6/33 | 1/34 | 2/115 |
| PYREXIAGeneral disorders | 9/34 | 11/33 | 6/34 | 21/115 |
| CONSTIPATIONGastrointestinal disorders | 9/34 | 9/33 | 3/34 | 34/115 |
| COUGHRespiratory, thoracic and mediastinal disorders | 10/34 | 7/33 | 6/34 | 16/115 |
| VOMITINGGastrointestinal disorders | 9/34 | 8/33 | 3/34 | 25/115 |
| HEADACHENervous system disorders | 9/34 | 7/33 | 7/34 | 24/115 |
| DIARRHOEAGastrointestinal disorders | 3/34 | 6/33 | 2/34 | 29/115 |
| DECREASED APPETITEMetabolism and nutrition disorders | 5/34 | 4/33 | 4/34 | 27/115 |
| FATIGUEGeneral disorders | 7/34 | 7/33 | 7/34 | 23/115 |
Three participants did not receive study treatment but are included in the baseline population.
| Age, Continuous(Years) | Group 1: 0.3 mg/kg | Group 1: 10 mg/kg | Group 2: 10 mg/kg | Group 3: 10 mg/kg | Total |
|---|---|---|---|---|---|
| Mean | 23.7 ± 15.5 | 20.1 ± 10.3 | 27.5 ± 15.3 | 24.6 ± 11.4 | 24.3 ± 12.8 |
| Sex: Female, Male(Participants) | Group 1: 0.3 mg/kg | Group 1: 10 mg/kg | Group 2: 10 mg/kg | Group 3: 10 mg/kg | Total |
|---|---|---|---|---|---|
| Female | 14 | 13 | 11 | 43 | 81 |
| Male | 21 | 20 | 24 | 73 | 138 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2008 to primary completion in Aug 2011, 42 months.
Results were first posted in Dec 2015, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.